coronary heart disease
Conditions
Interventions
Group 1:Take nattokinase capsules and monascus capsules. It contains active ingredients: Nattokinase: 600Fu*3 capsules/time, twice/day, about 4000Fu per day
Lovastatin: 1.5mg/ pill, 3 capsules/times, 2 times/day 9mg per day
Group 2:Take placebo capsules and nattokinase capsules. It contains active ingredients: Nattokinase: 600Fu*3 capsules/time, twice/day, about 4000Fu per day
Group 3:Take placebo capsules and monascus capsules. It contains active ingredients: Lovastatin: 1.5mg/ pill, 3 capsules/times, 2 times/day 9mg per day
Group4:Placebo capsule
Sponsors
School of Public Health, Qingdao University
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: (1) WHO diagnostic criteria for diagnosis of coronary heart disease or coronary angiography shows that the degree of stenosis of one major coronary artery or multiple coronary arteries is greater than or equal to 50%; (2) No health drugs such as nutritional supplements have been taken 3months before screening; (3) Voluntary signing of informed consent.
Exclusion criteria
Exclusion criteria: (1) Patients with severe liver and kidney diseases, tumors and peripheral vascular diseases, recent surgery and trauma; (2) complicates with other diseases, and researchers believe that it affects the efficacy evaluation or poor compliance; (3) For any other reason, the researcher considers it inappropriate to participate in the experiment.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| lipid;CK;LDH;ATIII;PLG;t-PA;PAI-1;TXB 2;6-Keto-PGF 1a;ET-1;intestinal flora; | — |
Secondary
| Measure | Time frame |
|---|---|
| Blood pressure;BMI; | — |
Countries
China
Contacts
Public ContactLiang Hui
School of Public Health, Qingdao University
Outcome results
None listed